The Eagle Eye Approach: Comprehensive Genomics Profile[CGP]

Authors

  • Rajavarman Kittu Reseacher, Premas Life Sciences Pvt Ltd., New Delhi, India.

Abstract

Ancient Medicine methods had Precision medicine concept only in traditional Ayurvedic methods. Since modern medicine adopted both genetics and genomics profiling, precision medicine is playing a major role in cancer patients' lives. This oncology Medicine has been taken to the next level while the comprehensive genomic profiling (CGP) gave hope of capturing all possible key elements through Next generation sequencing molecular approaches that contribute to the cancers. The combination of ACMG guidelines, FDA, and individual professional guidelines for therapy recommendation with all possible literature survey is making possible survival options, with less cost effective, great clinical utility options of disease management. This is attempted to discuss about how CGP has been analyzed by Clinical bioinformaticians and the impact of CGP.

References

Ménard T, Barros A, Ganter C. Clinical quality considerations when using next-generation sequenc-ing (NGS) in clinical drug development. Therapeutic Innovation & Regulatory Sci-ence. 2021 Sep;55(5):1066–74.

Metzker ML. Sequencing technologies-the next generation. Nature reviews genetics. 2010 Jan;11(1):31–46.

Genomics-driven oncology: framework for an emerging paradigm. Garraway LA., JCO. 2013;31(15):1806–14.

Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next generation sequenc-ing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. 2019:9–30.

Shylasree TS, Richa B, Lavanya G, Gulia S. Molecular Signatures of Gynecological Can-cers: Clini-cians Perspective. Indian Journal of Surgical Oncology. 2021 Apr;12(1):103–10.

Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through sec-ond-generation sequencing. Nature Reviews Genetics. 2010 Oct;11(10):685–96.

Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA oncolo-gy. 2015 Nov 1;1(8):1154–61.

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New England Journal of Medicine. 2013 Jun 20;368(25):2385–94.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in mel- anoma. N Engl J Med. 371:1877–1888.

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031–7.

Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a biomarker-based strategy on oncology drug devel-opment: a meta-analysis of clinical trials leading to FDA approval. Journal of the National Cancer In-stitute. 2015 Nov 1;107(11): djv253.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, San-ford EM, An P, Sun J. Development and validation of a clinical cancer ge-nomic profiling test based on mas-sively parallel DNA sequencing. Nature biotechnology. 2013 Nov;31(11):1023–31.

George TJ, Frampton GM, Sun J, Gowen K, Kennedy M, Greenbowe JR, Schrock AB, Ali SM, Klempner SJ, Hezel AF, Ross JS. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.

Downloads

Published

2022-09-02

Issue

Vol. 9 No. 2 (2022)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.